Ionis Pharmaceuticals (NASDAQ:IONS) is a biotech company which develops RNA-targeted therapeutics and has been operating for over 26 years. The company has recently filed to spin-off its Akcea Therapeutic segment, focused on Volanesorsen and other drugs related to cardiometabolic diseases originated by lipid disorders.
Ionis Core, the company core segment, has developed a broad pipeline of....More>>>
IN THE NEWS
The biotech sector saw a modest uptick this week amid a slew of biotech earnings news flow and a deal announced in the space: Link
Retailers have shown greater capital discipline in the hopes of re-invigorating their businesses, but investors must take a cautious stance on the sector, according to Morgan Stanley: Link
President Donald Trump said he was working....More>>>
Most of the time, quarterly financial results are important for companies. Investors eagerly await the update on revenue and earnings. But for Celldex Therapeutics (NASDAQ:CLDX), it’s a different story.
The big news everyone anxiously looked forward to for the clinical-stage biotech was the results from a pivotal clinical study glembatumumab vedotin (glemba) in treatingtriple negative....More>>>
Aclaris Therapeutics (NASDAQ:ACRS) received a $50.00 price target from equities research analysts at Cantor Fitzgerald in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 177.62% from the company’s current price.
ACRS has been the subject....More>>>
On November 25th, 2017, I first wrote about a small biotech called KemPharm (KMPH) and emphasized the importance of the ADHD portion of KemPharm’s pipeline. I wrote about Apadaz and the pain portion of KemPharm’s pipeline as somewhat of a liability, but believed that the substantial potential of the ADHD pipeline made the potential benefit outweigh the risks. On the next trading day....More>>>
Here’s what Jim Cramer had to say about some of the stocks during the Mad Money Lightning Round:
Waste Management (WM) : “This is a high quality stock so I’m not going to bet against it.”
The Blackstone Group (BX) : “I think this is a terrific buy.”
Xilinx (XLNX) : “I think it’s time to start getting back into NVIDIA (NVDA) .”
Puma Biotechnology Inc (NASDAQ:PBYI) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Puma Biotechnology Inc has a market cap of $3.03 billion; its shares were traded at around $80.75 with and P/S ratio of 495.40.....More>>>
Revance Therapeutics, Inc. (NASDAQ: RVNC) shares jumped 33.7 percent to $34.75 after the company disclosed that its RT002 met primary and all secondary endpoints.
Barnes & Noble Education, Inc. (NYSE: BNED) shares climbed 21.5 percent to $7.6200 after the company reported Q2 results.
Moleculin Biotech, Inc. (NASDAQ: MBRX) shares gained 18.9 percent to $2.1631 after....More>>>
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Merck has bad news in stomach cancer therapy
Company: Merck (MRK)
Disease: Gastric or gastroesophageal junction (GEJ) cancer
After the company announced top-line data from an important phase 3 trial, shares of Nabriva Therapeutics(NASDAQ:NBRV), a clinical-stage biotech focused on next-generation antibiotics, fell as much as 14% in morning trading on Monday. As of 11:20 a.m. EDT, the stock was down 9%.
Nabriva announced top-line results from its Leap 2 study today. This phase....More>>>